• linkedin
  • Increase Font
  • Sharebar

    Study: Active surveillance uptake remains low

    Surveillance use in low-risk prostate Ca varies significantly across facilities

    Boston—The overall use of active surveillance (AS) in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.

    In addition, variation in the use of AS is significant across facilities, reported Björn Löppenberg, MD, at the AUA annual meeting in Boston.

    Dr. LoppenbergDr. Loppenberg“Given current concerns for overdiagnosis and overtreatment of indolent prostate cancer, low rates and inconsistent use of active surveillance are alarming,” said Dr. Löppenberg, fellow in the division of urologic surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston.

    Recent reports on the utilization of AS in the U.S. have shown encouraging results. The Michigan Urological Surgery Improvement Collaborative (MUSIC) of 17 Michigan-based practices reported that 48% of eligible patients received AS. Other collectives report utilization rates of AS in the range of 40%.

    Also see: Top 9 peer-reviewed prostate cancer papers of 2017

    “However, these reports are limited to certain geographical regions or certain patient collectives,” he said.

    The Brigham and Women's Hospital group conducted a retrospective cohort study of 40,215 men with low-risk prostate cancer within the National Cancer Data Base, diagnosed in 2012 and 2013. Low risk was defined as cT1-cT2 disease with a serum PSA level <10.0 ng/mL and a Gleason score ≤6.

    “Additionally, we wanted to assess the variation in care; therefore, we used a mixed-effects model to assess which factors contribute to variation,” said Dr. Löppenberg, who worked on the study with Quoc-Dien Trinh, MD, and colleagues.

    Some 1,172 facilities were included in the analysis. Overall, 14.2% of eligible men received AS. The unadjusted rate in treatment variation ranged from 0 to 62% in facilities treating more than 75 patients within the study period.

    Next: Facility volume, type linked with AS

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • [email protected]
      This would be a meaningful MIPS question. If we're worried about still getting bone scans on very low risk prostate cancer we're all in trouble. Roscoe Nelson